Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Testare il trattamento con Encorafenib e Binimetinib prima dell'intervento chirurgico per il melanoma con coinvolgimento dei linfonodi

11 settembre 2026 aggiornato da: ECOG-ACRIN Cancer Research Group

Uno studio neoadiuvante di fase II su encorafenib con binimetinib in pazienti con metastasi locoregionali resecabili da melanoma primario cutaneo o sconosciuto (stadi III N1B/C/D)

This phase II trial studies how well encorafenib and binimetinib work before surgery in treating patients with BRAF V600-mutated stage IIIB-D melanoma that has spread to the lymph nodes. Encorafenib and binimetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. This trial also studies how well 18F-FLT positron emission tomography (PET)/computed tomography (CT) works in predicting the response of melanoma to encorafenib and binimetinib. 18F-FLT is an imaging agent, sometimes called a tracer. PET and CT are types of imaging scans. Using 18F-FLT PET/CT together with encorafenib and binimetinib may provide more information on melanoma over time.

Panoramica dello studio

Stato

Terminato

Condizioni

Intervento / Trattamento

Descrizione dettagliata

PRIMARY CLINICAL OBJECTIVE:

I. To evaluate the pathologic complete response (pCR) rate of neoadjuvant treatment with encorafenib and binimetinib.

SECONDARY CLINICAL OBJECTIVES:

I. To determine response rate (RR) (Response Evaluation Criteria in Solid Tumors [RECIST]), disease-free survival (DFS) and overall survival (OS).

II. To describe correlation of pCR with RR, DFS and OS. III. To assess safety and toxicity.

CORRELATIVE SCIENCE OBJECTIVES:

I. To evaluate CD8 positive (+) T cell infiltration and Ki-67 status in tumor or tumor bed pre, during, and post neoadjuvant treatment and the change in CD8+ tumor infiltrating lymphocyte (TIL) with neoadjuvant treatment and correlate with clinical response.

II. To compare local review for pathologic response with central pathology review.

III. To assess the correlation between change in fluorothymidine F-18 (18F-FLT) PET/CT uptake and change in Ki-67.

IMAGING OBJECTIVES:

I. To compare the change in 18F-FLT PET/CT uptake (from baseline to post-neoadjuvant therapy) among patients with and without pathologic complete response.

II. To compare post-neoadjuvant 18F-FLT PET/CT uptake among patients with and without pathologic complete response.

III. To estimate an optimal threshold for prediction of pathologic complete response using i) change in 18F-FLT PET/CT uptake, and ii) post-neoadjuvant 18F-FLT PET/CT uptake.

IV. To assess the correlation between change in 18F-FLT PET/CT uptake and change in Ki-67.

OUTLINE:

NEOADJUVANT TREATMENT: Patients receive 18F-FLT intravenously (IV) and undergo a PET/CT scan approximately 60 minutes later. Within 2 weeks, patients receive encorafenib orally (PO) once daily (QD) and binimetinib PO twice daily (BID) on days 1-28. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive 18F-FLT IV and undergo a second PET/CT scan approximately 60 minutes later.

SURGICAL RESECTION: Within 2 weeks of completing therapy with encorafenib and binimetinib, patients undergo surgery.

ADJUVANT TREATMENT: Within 2-7 days after surgery, patients resume treatment with encorafenib PO QD and binimetinib PO BID on days 1-28. Treatment repeats every 28 days for up to 11 cycles in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up every 3 months for 1 year, then every 6 months for 3 years.

Tipo di studio

Interventistico

Iscrizione (Effettivo)

3

Fase

  • Fase 2

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

    • California
      • Los Angeles, California, Stati Uniti, 90033
        • USC / Norris Comprehensive Cancer Center
      • Los Angeles, California, Stati Uniti, 90033
        • Los Angeles County-USC Medical Center
    • Michigan
      • Ann Arbor, Michigan, Stati Uniti, 48109
        • University of Michigan Comprehensive Cancer Center
    • Missouri
      • City of Saint Peters, Missouri, Stati Uniti, 63376
        • Siteman Cancer Center at Saint Peters Hospital
      • Creve Coeur, Missouri, Stati Uniti, 63141
        • Siteman Cancer Center at West County Hospital
      • St Louis, Missouri, Stati Uniti, 63110
        • Washington University School of Medicine
      • St Louis, Missouri, Stati Uniti, 63129
        • Siteman Cancer Center-South County
      • St Louis, Missouri, Stati Uniti, 63136
        • Siteman Cancer Center at Christian Hospital
    • Pennsylvania
      • Philadelphia, Pennsylvania, Stati Uniti, 19111
        • Fox Chase Cancer Center
    • Wisconsin
      • Madison, Wisconsin, Stati Uniti, 53792
        • University of Wisconsin Carbone Cancer Center

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Patient must have histologically proven melanoma that is clinically evident (macroscopic lymphadenectomy [LAD]) stage III B/C/D, (American Joint Committee on Cancer [AJCC] 8th edition) of cutaneous origin or unknown primary. Patients must have at least one clinically evident lymph node metastasis (N1c patients are not eligible).

    • This may be an initial presentation with primary tumor and nodal metastases or locoregional nodal relapse with history of resected primary melanoma

    • Stage IIIB

      • T0-3a N1b M0
      • T1a-3a N2b M0
    • Stage IIIC

      • T0 or T3b-4b N2b M0
      • T3b-4b N1b M0
      • Any T N2c M0 (at least 1 clinically evident node)
      • T0-4a N3b M0
    • Stage IIID

      • T4b N3b/c M0 (if 3c: at least 1 clinically evident node)
  • Patient must have measurable disease on baseline imaging scans, obtained within 4 weeks prior to registration as defined by RECIST and by the following criteria

    • The melanoma target tumor must be completely resectable as determined by a surgical oncologist or experienced melanoma surgeon

      • Extensive satellitosis or in transit metastases are not considered completely resectable
  • Patient must have BRAF V600 mutation positive based on report from Clinical Laboratory Improvement Act (CLIA) certified laboratory

  • Patient must be medically fit to undergo surgery

  • Absolute neutrophil count (ANC) >= 1.5 x 10^9/L (obtained < 14 days prior to registration)

  • Hemoglobin >= 8 g/dL without transfusion (obtained < 14 days prior to registration)

  • Platelets >= 100 x 10^9/L without transfusion (obtained < 14 days prior to registration)

  • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.0 x upper limit of normal (ULN) (obtained < 14 days prior to registration)

  • Total bilirubin =< 1.5 x ULN and < 2 mg/dL; OR total bilirubin > 1.5 x ULN with indirect bilirubin < 1.5 x ULN (obtained < 14 days prior to registration)

  • Serum creatinine =< 1.5 x ULN, or calculated creatinine clearance > 50 mL/min by Cockcroft-Gault formula (obtained < 14 days prior to registration)

  • Prothrombin time (PT), international normalized ratio (INR), and partial thromboplastin time (PTT) =< 1.5 x ULN (obtained < 14 days prior to registration)

  • Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status 0-1

  • Patient must be able to take oral medications

  • Patient must be able to lie still during the 18F-FLT PET/CT scan for the duration of the imaging study (up to 1.5 hours), have no previous indication of allergic reaction to the radiotracer, and meet the size limits of the qualified PET/CT scanner

  • Patient must be participating in this study at an institution which has completed the ECOG-American College of Radiology Imaging Network (ACRIN) defined PET/CT scanner qualification procedures and received ECOG-ACRIN PET scanner approval

  • Patients known to be human immunodeficiency virus (HIV) positive are eligible if they have undetectable HIV viral load and stable and adequate CD4 counts (>= 500 mm^3) on screening labs provided they meet all other protocol criteria for participation and that there is no high risk drug interactions

  • Women of childbearing potential and sexually active males must use accepted and effective method(s) of contraception or to abstain from sexual intercourse for the duration of their participation in the study and for at least 30 days after the last dose of protocol treatment for female patients, and for at least 90 days after the last dose of protocol treatment for male patients. In addition, female patients must not donate ova from the time of registration until 30 days after the last dose of study treatment. Male patients must not donate sperm from the time of registration until 90 days after the last dose of protocol treatment

  • Patient may be on anticoagulation at prophylactic or therapeutic levels. Patients must not be using anticoagulants at therapeutic levels that may interfere with encorafenib and binimetinib

Exclusion Criteria:

  • Stage IV melanoma

  • Patient must not have any prior treatment with BRAF inhibitor (BRAFi) or MEK inhibitor (MEKi)

  • Patient must not have any evidence of distant metastases

  • Patient must not have any prior adjuvant therapy at this disease presentation; prior immune therapy (such as adjuvant interferon or checkpoint inhibitors) is permitted if >= 6 months from last treatment

  • Patient must not have any prior radiation to the site of evaluable disease

  • Patient must not have active infection requiring treatment with parenteral antibiotics

  • Patient must not have active hepatitis B, and/or active hepatitis C infection given concerns for drug interactions or increased toxicities. Testing is not required

  • Patient must not have other significant medical, surgical, or psychiatric conditions that in the opinion of the investigator may interfere with compliance, make the administration of study medications hazardous

  • Patient must not have had previous or concurrent other malignancy with the following exceptions:

    • Adequately treated basal cell or squamous cell carcinoma of the skin, in situ carcinoma of the cervix
    • Other solid tumor: if treated and without evidence of recurrence for at least 2 years prior to study entry
  • Women must not be pregnant or breast-feeding due to potential harm to an unborn fetus and possible risk for adverse events in nursing infants with the systemic antineoplastic medications, as well as surgery and radiation being used. Patients must also not expect to conceive or father children from the time of registration, while on study, treatment, and until at least 30 days after the last dose of study treatment (for female patients) and 90 days after the last dose of study treatment (for male patients). All females of childbearing potential must have a blood test or urine study within 14 days prior to registration to rule out pregnancy. A female of childbearing potential is any woman, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy; or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)

  • Patient must not have known hypersensitivity or contraindication to any component of binimetinib or encorafenib or their excipients

  • Patient must not have impaired cardiovascular function or clinically significant cardiovascular disease including, but not limited to, any of the following:

    • History of acute coronary syndromes (including myocardial infarction, unstable angina, coronary artery bypass grafting, coronary angioplasty or stenting) < 6 months prior to registration
    • Congestive heart failure requiring treatment (New York Heart Association grade >= 2)
    • Left ventricular ejection fraction (LVEF) < 50% as determined by multigated acquisition scan (MUGA) or echocardiogram (ECHO)
    • Uncontrolled hypertension defined as persistent systolic blood pressure >= 150 mmHg or diastolic blood pressure >= 100 mmHg despite current therapy
    • History or presence of clinically significant cardiac arrhythmias (including resting bradycardia, uncontrolled atrial fibrillation or uncontrolled paroxysmal supraventricular tachycardia)
    • Baseline corrected QT (QTc) interval >= 480 ms
  • Patient must not have impairment of gastrointestinal function or disease which may significantly alter the absorption of study drug (e.g., active ulcerative disease, uncontrolled vomiting or diarrhea, malabsorption syndrome, small bowel resection with decreased intestinal absorption), or recent (=< 3 months) history of a partial or complete bowel obstruction, or other conditions that will interfere significantly with the absorption of oral drugs

  • Patient must not have any known history of acute or chronic pancreatitis

  • Patient must not have any concurrent neuromuscular disorder that is associated with elevated creatine kinase (CK) (e.g., inflammatory myopathies, muscular dystrophy, amyotrophic lateral sclerosis, spinal muscular atrophy

  • Patient must not have any known history or current evidence of retinal vein occlusion (RVO) or current risk factors for RVO (e.g., uncontrolled glaucoma or ocular hypertension, history of hyperviscosity, factor V Leiden or activated protein C resistance); history of retinal degenerative disease

  • Patient must not use any medication (including herbal medications, supplements, or foods), or use of a prohibited medication =< 1 week prior to registration

  • Patient must not have a history of thromboembolic or cerebrovascular events =< 12 weeks prior to registration. Examples include transient ischemic attacks, cerebrovascular accidents, hemodynamically significant (i.e. massive or sub-massive) deep vein thrombosis or pulmonary emboli

    • NOTE: Patients with thromboembolic events related to indwelling catheters or other procedures may be registered
    • NOTE: Patients with either deep vein thrombosis or pulmonary emboli that does not result in hemodynamic instability are allowed to register as long as they are on a stable dose of anticoagulants for at least 4 weeks

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: N / A
  • Modello interventistico: Assegnazione di gruppo singolo
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Neoadjuvant encorafenib + binimetinib, surgery, adjuvant encorafenib + binimetinib

NEOADJUVANT TREATMENT: Patients receive 18F-FLT IV and undergo a PET/CT scan approximately 60 minutes later. Within 2 weeks, patients receive encorafenib PO QD and binimetinib PO BID on days 1-28. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive 18F-FLT IV and undergo a second PET/CT scan approximately 60 minutes later.

SURGICAL RESECTION: Within 2 weeks of completing therapy with encorafenib and binimetinib, patients undergo surgery.

ADJUVANT TREATMENT: Within 2-7 days after surgery, patients resume treatment with encorafenib PO QD and binimetinib PO BID on days 1-28. Treatment repeats every 28 days for up to 11 cycles in the absence of disease progression or unacceptable toxicity.

Undergo surgery

Given PO

Altri nomi:
  • ARRY-438162
  • MEK162
  • Mektovi
  • NSC 788187

Given PO

Altri nomi:
  • LGX818
  • ONO-7702

Given IV

Altri nomi:
  • 18F-FLT
  • FLT
  • 3'-DEOXY-3'- 18F Fluorotimidina

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Pathologic Complete Response
Lasso di tempo: Assessed at 10-12 weeks

Pathologic complete response (pCR) is defined as complete absence of viable tumor in the treated tumor bed. Partial pathologic response (pPR) is defined as less than or equal to 50% of the treated tumor bed is occupied by viable tumor cells. Pathologic non-response is defined as great than 50% of the treated tumor bed is occupied by viable tumor cells.

Assessed at 10-12 weeks

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Objective Response
Lasso di tempo: Assessed at baseline, 8 weeks, then every 12 weeks up to 1.4 years

Objective response is defined as either complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1). Complete response is defined as disappearance of all lesions. Partial response is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters and/or persistence of one or more non-target lesion(s). Stable disease is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the smallest sum diameters while on study. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study or appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions.

Assessed at baseline, 8 weeks, then every 12 weeks up to 1.4 years
Disease-free Survival
Lasso di tempo: Assessed at baseline, 8 weeks, then every 12 weeks up to 19.4 months

Disease-free survival is defined as the time from date of surgical resection to the date of recurrence or death, whichever occurs first.

Recurrence must be documented by radiologic exams and with biopsy in all cases except for brain metastases (biopsy not required). Abnormal blood studies alone (e.g., elevated transaminases or alkaline phosphatase) are not sufficient evidence of relapse. Whenever possible, histologic proof of recurrence should be obtained unless the lesion is not accessible or a biopsy would cause undue risk to the patient.

Assessed at baseline, 8 weeks, then every 12 weeks up to 19.4 months
Overall Survival
Lasso di tempo: Assessed at every 3 months for 2 years and then every 6 months, up to 2 years 9 months

Overall survival is defined as the time from registration to death or date last known alive, which is the censoring date for patients who are still alive.

Assessed at every 3 months for 2 years and then every 6 months, up to 2 years 9 months
Associations Between pCR and Best Response
Lasso di tempo: Assessed at baseline, 8 weeks, then every 12 weeks up to 1.4 years

Association between pCR and best response will be reported.

Assessed at baseline, 8 weeks, then every 12 weeks up to 1.4 years

Altre misure di risultato

Misura del risultato
Misura Descrizione
Lasso di tempo
CD8+ T Cell Infiltration and Ki-67 Status
Lasso di tempo: Assessed at baseline, during neoadjuvant treatment and at surgery

Evaluation of CD8+ T cell infiltration and Ki-67 status in tumor or tumor bed pre, during, and post neoadjuvant treatment will be performed. The change in CD8+ TIL with neoadjuvant treatment will also be evaluated.

Assessed at baseline, during neoadjuvant treatment and at surgery
Concordance Between Local Review for Pathologic Response and Central Pathology Review
Lasso di tempo: Assessed at surgery

The concordance between local review for pathologic response and central pathology review will be performed.

Assessed at surgery
Change in 18F-FLT PET/CT Uptake
Lasso di tempo: Assessed at baseline and post-neoadjuvant therapy

Comparison of the change in 18F-FLT PET/CT uptake from baseline to post-neoadjuvant therapy between patients with and without pathologic complete response will be performed.

Assessed at baseline and post-neoadjuvant therapy
18F-FLT PET/CT Uptake
Lasso di tempo: Assessed after neoadjuvant treatment, about 16 weeks

The uptake value of 18F-FLT PET/CT will be evaluated after neoadjuvant treatment is completed. This value will be compared between patients with and without pathologic complete response.

Assessed after neoadjuvant treatment, about 16 weeks
Association Between Pathologic Complete Response and Change in 18F-FLT PET/CT Uptake as Well as Post-neoadjuvant 18F-FLT PET/CT Uptake
Lasso di tempo: Assessed at baseline and post-neoadjuvant treatment

The association between pathologic complete response and change in 18F-FLT PET/CT uptake as well as post-neoadjuvant 18F-FLT PET/CT uptake will be evaluated. An optimal threshold of 18F-FLT PET/CT uptake for prediction of pathologic complete response will be estimated.

Assessed at baseline and post-neoadjuvant treatment
Correlation Between Change in 18F-FLT PET/CT Uptake and Change in Ki-67
Lasso di tempo: Assessed at baseline and post-neoadjuvant treatment

The correlation between change in 18F-FLT PET/CT uptake and change in Ki-67 will be evaluated.

Assessed at baseline and post-neoadjuvant treatment

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Collaboratori

Investigatori

  • Investigatore principale: Leslie A Fecher, ECOG-ACRIN Cancer Research Group

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

22 settembre 2021

Completamento primario (Effettivo)

10 giugno 2024

Completamento dello studio (Effettivo)

31 gennaio 2025

Date di iscrizione allo studio

Primo inviato

6 gennaio 2020

Primo inviato che soddisfa i criteri di controllo qualità

6 gennaio 2020

Primo Inserito (Effettivo)

9 gennaio 2020

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

6 ottobre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

11 settembre 2026

Ultimo verificato

1 settembre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • EA6183
  • U10CA180820 (Sovvenzione/contratto NIH degli Stati Uniti)
  • EA6183 (Altro identificatore: CTEP)
  • NCI-2019-07407 (Identificatore di registro: CTRP (Clinical Trial Reporting Program))
  • EA6183 (Altro identificatore: ECOG-ACRIN Cancer Research Group)

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Descrizione del piano IPD

Individual participant data may be made available upon request as per the ECOG-ACRIN Data Sharing Policy.

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .